Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus

3002309
copy
 

Copy Utility


emailprint
Example Reports
Enhanced Report
Not Performed
Performed

Ordering Recommendation

Assess risk of ovarian cancer in women who present with an adnexal mass.

Mnemonic

OVA1 PLUS

Methodology

Electrochemiluminescent Immunoassay (ECLIA)/Fixed-Rate-Time Nephelometry

Performed

Varies

Reported

4-8 days
N/A

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Serum Separator Tube (SST).

Specimen Preparation

Transfer 2.2 mL serum to an ARUP Standard Transport Tube. (Min: 1.1 mL)

Storage/Transport Temperature

Frozen. Also acceptable: Refrigerated.

Unacceptable Conditions
Remarks

Menopausal Status required at time of ordering.

Stability

Ambient: Unacceptable; Refrigerated: 8 days; Frozen: 9 weeks

Reference Interval

By Report

Interpretive Data



Compliance Category

Performed by non-ARUP Laboratory

Note

OVA1 Biomarkers: CA-125 II, Apoliproprotein A1 (Apo A-1), Beta-2 Microglobulin (B2M), Transferrin, and Prealbumin.

OVERA Biomarkers: Apolipoprotein A1 (Apo A-1), HE4 (Human Epididymis protein 4), CA-125 II, FSH (Follicle Stimulating Hormone), and Transferrin.

Hotline History

N/A

CPT Codes

81503

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
3002310 EER Malignancy Assessment, OVA1 Plus 11502-2
3002311 Malignancy Assessment, Menopausal Status
3002312 Malignancy Assessment, CA 125 II
3002313 Malignancy Assessment, OVA1 Score
3002615 Malignancy Assessment, OVERA Score
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus

ASPiRA Labs, Inc